Smith & Nephew plc (LON:SN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 9.50B +0.4% |
| Revenue (ttm) | 4.58B +6.1% |
| Net Income | 464.38M +51.7% |
| EPS | 0.53 +52.3% |
| Shares Out | 854.05M |
| PE Ratio | 20.90 |
| Forward PE | 13.35 |
| Dividend | 0.29 (2.61%) |
| Ex-Dividend Date | Mar 26, 2026 |
| Volume | 2,165,122 |
| Average Volume | 3,136,484 |
| Open | 1,102.00 |
| Previous Close | 1,104.00 |
| Day's Range | 1,102.00 - 1,118.50 |
| 52-Week Range | 1,051.47 - 1,441.50 |
| Beta | 0.67 |
| RSI | 38.66 |
| Earnings Date | Aug 4, 2026 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform m... [Read more]
Financial Performance
In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.
Financial numbers in USD Financial StatementsNews
Smith & Nephew price target lowered to $30 from $32 at Canaccord
Canaccord lowered the firm’s price target on Smith & Nephew to $30 from $32 and keeps a Hold rating on the shares. The firm updated its model following Q1 results…
Smith & Nephew price target lowered to $31.85 from $36.20 at Bernstein
Bernstein lowered the firm’s price target on Smith & Nephew to $31.85 from $36.20 and keeps a Market Perform rating on the shares after the company provided a Q1 trading…
Cevian Capital II GP LTD Acquires Significant Stake in Smith & Nephew PLC
Cevian Capital II GP LTD Acquires Significant Stake in Smith & Nephew PLC
Smith & Nephew and Four More Stocks See Action From Activist Investors
Smith & Nephew To Repurchase Up To $250 Mln Of Shares
(RTTNews) - Smith & Nephew PLC (SNN, SN.L), a medical technology company, said on Friday that it has inked a deal with Merrill Lynch International to repurchase up to $250 million of shares at $0.20 p...
Smith & Nephew price target raised to 1,350 GBp from 1,300 GBp at Barclays
Barclays raised the firm’s price target on Smith & Nephew to 1,350 GBp from 1,300 GBp and keeps an Equal Weight rating on the shares. Th firm updated the company’s
Smith & Nephew Earnings Call Transcript: Q1 2026
Q1 delivered 3.1% underlying growth, led by Sports Medicine and resilient Advanced Wound Management, offsetting softness in U.S. knees. Full-year guidance is reaffirmed, with a $500 million share buyback announced and strong cash generation supporting future growth.
UK's Smith+Nephew keeps annual outlook, plans share buyback as quarterly revenue rises
Medical products maker Smith+Nephew posted a 3.1% rise in first-quarter underlying revenue on Wednesday, helped by strong sports medicine and wound management performance, and kept its annu...
Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming Europ...
Is Smith & Nephew PLC (SNN) a Bargain After 3.1% Drop? GF Value Says Undervalued
Is Smith & Nephew PLC (SNN) a Bargain After 3.1% Drop? GF Value Says Undervalued
Smith & Nephew price target lowered to $32 from $35 at Canaccord
Canaccord analyst Caitlin Cronin lowered the firm’s price target on Smith & Nephew to $32 from $35 and keeps a Hold rating on the shares. The firm updated its model
A Look at Smith & Nephew PLC (SNN) After 4.0% Decline -- GF Value $31.12 vs Price $32.84
A Look at Smith & Nephew PLC (SNN) After 4.0% Decline -- GF Value $31.12 vs Price $32.84
Smith+Nephew (SNN) Reports Positive Trial Results for Cartilage Repair Implant
Smith+Nephew (SNN) Reports Positive Trial Results for Cartilage Repair Implant
Smith & Nephew announces evidence for Cartiheal Agili-C Cartilage Repair
Smith+Nephew announces further evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its Cartiheal Agili-C Cartilage Repair Implant recently published in th...
Smith & Nephew Breaks Above 200-Day Moving Average - Bullish for SNN
In trading on Tuesday, shares of Smith & Nephew plc (Symbol: SNN) crossed above their 200 day moving average of $34.14, changing hands as high as $34.41 per share. Smith & Nephew plc shares are curren...
Smith & Nephew reports positive trial data for Regeneten implant
Smith & Nephew announced compelling new randomized control trial data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated with the Regeneten bioi...
Smith & Nephew price target raised to 1,507 GBp from 1,482 GBp at Morgan Stanley
Morgan Stanley raised the firm’s price target on Smith & Nephew to 1,507 GBp from 1,482 GBp and keeps an Overweight rating on the shares.
Smith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, recently announced the launch of ALLEVYN♢ COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed...
Smith & Nephew price target raised to $35 from $34 at Canaccord
Canaccord raised the firm’s price target on Smith & Nephew to $35 from $34 and keeps a Hold rating on the shares. The firm said they delivered a solid quarter,
Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026
Smith+Nephew announces it will feature handheld robotics during the American Academy of Orthopedic Surgeons (AAOS) Annual meeting in New Orleans this week.
Smith & Nephew price target raised to 1,305 GBp from 1,290 GBp at Barclays
Barclays raised the firm’s price target on Smith & Nephew to 1,305 GBp from 1,290 GBp and keeps an Equal Weight rating on the shares.
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026
Uniting the most advanced technologies for biomechanical repair and biological augmentation Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase it...
Smith & Nephew Earnings Call Transcript: Q4 2025
Delivered strong FY2025 results with 5.3% revenue growth, 160 bps margin expansion, and $840M free cash flow. 2026 guidance targets 6% organic revenue growth and $1.3B trading profit, with innovation and new launches driving performance.
UK medical products maker Smith & Nephew's annual profit jumps 15.5%
British medical products maker Smith & Nephew posted a 15.5% jump in annual profit on Monday, building on the success of its turnaround plans, which delivered cost savings and boosted growth across it...
Smith & Nephew announces U.S. distribution agreement with RMR Ortho
Smith+Nephew announces it has signed an exclusive U.S. distribution agreement with RMR Ortho to add the A’TOMIC Nitinol Fixation System to the Smith+Nephew Trauma, Foot & Ankle and Hand &